Coulter Partners supports Bluebee in appointment of Chairman and Non-Executive Director to the Board of Directors
Coulter Partners was delighted to work with Bluebee, a leading provider of high performance genomics solutions, to secure the appointment of two new members to its Board of Directors. Lars Kongbak has been appointed as an independent director, and Nicolas Roelofs will become Chairman of the Board. Bluebee (www.bluebee.com) provides high performance genomics solutions, enabling genomic labs to substantially reduce cost and time-to-diagnosis. Bluebee’s unique cloud-based accelerated genomics platform enables fast, efficient and affordable processing of large volumes of genomics data.
“We conducted an exhaustive search for people who would further strengthen our board’s breadth of talent and background, and we are delighted to have identified such outstanding individuals with the support of the exceptional search team at Coulter Partners,” says Hans Cobben, CEO of Bluebee. “Both Nick Roelofs and Lars Kongsbak will bring a unique perspective and tremendous depth of experience and knowledge, especially in building a global business across both developed and emerging markets.”
An Industrial Advisor with Nordic Capital LTD, Nicolas Roelofs has gained significant experience within the life science industry over the last 30 years especially in international business. Previously he was at Agilent Technologies Inc. Life Sciences Group where, as President, he realized a number of acquisitions, including that of Dako. He oversaw the restructuring of the company and was responsible for delivering organic company growth well above the market average.
“Bluebee is at a special point in its development both as a business and as an organization,” adds Nicolas Roelofs. “I look forward to contributing to the future direction and growth of Bluebee, using my knowledge and past experiences. I am particularly excited that Hans and the team share my passion for building a successful and positive culture.”
Lars Kongsbak is involved with several life science companies where he has developed strong skills and a proven track record in drafting strategies, based on customer, market and technology inputs, and improving profitability. He has gained significant experience, including as Chairman of the Board of Directors of Virogates A/S and as CEO and President of Exiqon A/S. He has been responsible for efficient international commercialization and company growth, a successful IPO and many out-licensing deals.
“There is a strong need in the market for a secure platform for genetic analysis and easy retrieval of raw and analyzed genetic data. This is not served well today and I strongly believe that Bluebee can make a difference in this market,” comments Lars Kongsbak. “The strategy of serving the end-users through third parties is brilliant; secure cloud solutions are invaluable and outsourcing to specialists like Bluebee allows the focus to stay on understanding the samples.”